Longeveron Reports Q1 2026 Financial Results and Business Update
Decision brief
Answer first · skim in under a minute
Longeveron has released its financial results for the first quarter of 2026, along with significant updates on its clinical trials. This news is crucial for investors and business development teams tracking the company's progress.
Longeveron reports Q1 2026 financial results and business update with flat $0.4 million revenue, a narrower $4.7 million net loss, and $15.8 million in cash expected to fund operations into the fourth quarter of 2026.
Contents9 sections
Key Takeaways
- Q1 2026 revenue $0.4 million (flat year over year); net loss $4.7 million versus $5.0 million in Q1 2025.
- Cash and equivalents $15.8 million as of March 31, 2026; company guides runway into Q4 2026 on current budget.
- March 2026 private placement of up to $30 million ($15 million upfront; additional $15 million milestone-tied to ELPIS II/HLHS results and share price).
- Laromestrocel Phase 2b ELPIS II top-line timing has been framed around mid-to-late 2026 in company updates.
What did Longeveron report for Q1 2026?
On May 13, 2026, Longeveron Inc. (NASDAQ: LGVN) reported results for the quarter ended March 31, 2026. Revenue was $0.4 million, including about $0.4 million of clinical trial revenue and $20,000 of contract manufacturing revenue. Gross profit was $0.3 million. Net loss was $4.7 million, down 6% from $5.0 million a year earlier.
Source: GlobeNewswire — Longeveron Q1 2026 results.
How long is the cash runway?
Cash and cash equivalents were $15.8 million at March 31, 2026. Management said existing cash should fund operating expenses and capital expenditures into the fourth quarter of 2026 based on the current operating budget, while noting substantial ongoing costs and intent to seek additional financing or non-dilutive funding.
- Cash: $15.8 million (March 31, 2026)
- Guided runway: into Q4 2026
- G&A: $2.7 million (down 7% year over year)
- Ticker: LGVN
What financing and clinical catalysts matter next?
In March 2026 the company completed a private placement of up to $30 million led with participation from named institutional investors, structured as $15 million upfront plus a potential additional $15 million tied to Phase 2b ELPIS II results in hypoplastic left heart syndrome (HLHS) and share-price conditions. Investors should separate the funded tranche from contingent capital.
Full-year 2025 context is in the March 17, 2026 results release: GlobeNewswire — Longeveron FY2025 results.
What should BD and investors model carefully?
Longeveron remains clinical-stage. Revenue is registry/manufacturing scale, not product sales. Dilution risk remains if the contingent $15 million does not fund or if ELPIS II disappoints. Partnership or licensing outcomes are stated goals in company messaging but are not closed deals in these releases.
What remains unproven?
These releases do not establish Phase 2b success for laromestrocel, FDA approval timelines, or that contingent private-placement capital will fund. Do not invent enrollment counts or endpoint effect sizes beyond what the company discloses in the cited wires.
Related NovaPharma coverage
Frequently Asked Questions
What were Longeveron’s Q1 2026 revenue and net loss?
Longeveron reported $0.4 million in revenue and a $4.7 million net loss for the quarter ended March 31, 2026, compared with a $5.0 million net loss in Q1 2025.
How much cash did Longeveron hold at quarter end?
The company reported $15.8 million in cash and cash equivalents as of March 31, 2026, and said that cash should fund operations into the fourth quarter of 2026 on its current budget.
What is the structure of the March 2026 private placement?
Longeveron described a private placement of up to $30 million with $15 million funded upfront and up to $15 million additional capital tied to Phase 2b ELPIS II HLHS results and share-price conditions.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
